SLC5A2 and type 2 diabetes mellitus: This study highlights the importance of considering individual patient characteristics, including baseline HbA1c levels, when selecting between SGLT2 inhibitors and DPP-4 inhibitors for optimal outcomes in type 2 diabetes management